• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent
 

Epilepsy

Although there has been a steady strategic decline in epilepsy research within the pharmaceutical industry over recent years, here at Transpharmation we still conduct preclinical epilepsy screens to support niche drug discovery programmes and therapeutic index assessment of NCEs regularly. Also, since many compounds demonstrating efficacy in pain assays are also anti-epileptic, our epilepsy models are often used as a rapid PD screen or novel analgesics prior to evaluation in more complex neuropathic pain assays.

All our epilepsy models are well-validated with clinical gold standards such as lamotrigine, diazepam and carbamazepine. Routine plasma/tissue sample collection verifies the establishment of PK/PD relationships.

Examples of the models we offer include the following:

  • Electrically induced seizures, e.g. MES, MEST, minEST, 6-Hz
  • Chemically evoked seizures, e.g. kainate, pentylenetetrazol, Harmaline-induced-tremor
  • Telemeterised EEG monitoring of brain seizure activity
  • Detailed scoring of behavioural seizures according to Racine’s scale
  • Concomitant assessment of therapeutic index utilising rotarod and LABORAS
  • Identification of additional therapeutic utilities of novel anticonvulsants e.g. for treatment of neuropathic pain.

epilepsyThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk


Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design